Education
About Us
Working with TipRanks
Follow Us
Silexion Therapeutics Corp (SLXN)
:SLXN
SLXN Stock Chart & Stats
$2.21
-$0.10(-4.76%)
At close: 4:00 PM EST
$2.21
-$0.10(-4.76%)
Day’s Range― - ―
52-Week Range$2.13 - $53.85
Previous CloseN/A
Volume52.80K
Average Volume (3M)61.14K
Market Cap
$8.79M
Enterprise Value-$3.39M
Total Cash (Recent Filing)$9.24M
Total Debt (Recent Filing)$485.00K
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Mar 24, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding3,126,642
10 Day Avg. Volume50,728
30 Day Avg. Volume61,140
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)-47.15
Price to Sales (P/S)0.00
P/FCF Ratio-22.34
Enterprise Value/Market Cap-0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit484.71
Enterprise Value/Ebitda0.45
Forecast
1Y Price Target
$12.00Price Target Upside442.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-12.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DataPositive pre-clinical data showing pan-KRAS inhibition by SIL-204 indicates a significant market opportunity in addressing unmet needs in pancreatic cancer.
Market OpportunitySilexion's market cap is under $10 million, suggesting that the stock may be overlooked by investors, presenting a potentially attractive investment opportunity.
Regulatory ApprovalPositive feedback from German regulatory authorities for the Phase 2/3 clinical trial design for SIL-204 positions Silexion to file a Clinical Trial Application in Germany.
Bears Say
Financial ResourcesCash should be sufficient to initiate the Phase 2/3 trial, but additional capital will likely be required to complete the trial.
Stock ValuationThe 12-month price target has been lowered to $12.00 from $24.00 due to the inclusion of additional shares from the capital raise.
Silexion Therapeutics News
SLXN FAQ
What was Silexion Therapeutics Corp’s price range in the past 12 months?
Silexion Therapeutics Corp lowest stock price was $2.13 and its highest was $53.85 in the past 12 months.
What is Silexion Therapeutics Corp’s market cap?
Silexion Therapeutics Corp’s market cap is $8.79M.
When is Silexion Therapeutics Corp’s upcoming earnings report date?
Silexion Therapeutics Corp’s upcoming earnings report date is Mar 24, 2026 which is in 99 days.
How were Silexion Therapeutics Corp’s earnings last quarter?
Silexion Therapeutics Corp released its earnings results on Nov 12, 2025. The company reported -$2.88 earnings per share for the quarter, beating the consensus estimate of -$3.4 by $0.52.
Is Silexion Therapeutics Corp overvalued?
According to Wall Street analysts Silexion Therapeutics Corp’s price is currently Undervalued.
Does Silexion Therapeutics Corp pay dividends?
Silexion Therapeutics Corp does not currently pay dividends.
What is Silexion Therapeutics Corp’s EPS estimate?
Silexion Therapeutics Corp’s EPS estimate is -1.07.
How many shares outstanding does Silexion Therapeutics Corp have?
Silexion Therapeutics Corp has 3,126,642 shares outstanding.
What happened to Silexion Therapeutics Corp’s price movement after its last earnings report?
Silexion Therapeutics Corp reported an EPS of -$2.88 in its last earnings report, beating expectations of -$3.4. Following the earnings report the stock price went up 3.559%.
Which hedge fund is a major shareholder of Silexion Therapeutics Corp?
Currently, no hedge funds are holding shares in SLXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Silexion Therapeutics Corp
Silexion Therapeutics (SLXN) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for rare and complex diseases. Operating within the biotechnology and pharmaceuticals sector, Silexion Therapeutics specializes in creating targeted treatments that address unmet medical needs, leveraging advanced genetic and molecular technologies to develop its core products.
SLXN Stock 12 Month Forecast
Average Price Target
$12.00
▲(442.99% Upside)